Growth factor usage patterns and outcomes in the community setting: Collection through a practice-based computerized clinical information system

Journal of Clinical Oncology

Volumn 18, Issue 8, 2000, Pages 1764-1770

  Swanson, Grant ^a   Bergstrom, Kim ^a   Stump, Eva ^a   Miyahara, Tammi ^a   Herfindal, E T ^a  

^a OnCare Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR;

ARTICLE; BREAST CANCER; CANCER THERAPY; CLINICAL PRACTICE; HUMAN; INFORMATION SCIENCE; INFORMATION SYSTEM; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; OUTCOMES RESEARCH; OVARY CANCER; PRIORITY JOURNAL;

EID: 0034003365     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.8.1764     Document Type: Article

References (16)

1. American Society of Clinical Oncology: Recommendations for the use of hematopoietic colony-stimulating factors: Evidenced-based clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
2. Oxer H, Miller LL, Schiff CA, et al: Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence based clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996
3. Bennett CL, Smith TJ, Weeks JC, et al: Use of hematopoietic colony stimulating factors: The American Society of Clinical Oncology survey. J Clin Oncol 14:2511-2520, 1996
4. Bennett CL, Weeks JA, Somerfield MR, et al: Use of hematopoietic colony-stimulating factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys regarding ASCO clinical practice guidelines. J Clin Oncol 17:3676-3681, 1999
5. Lieschke GJ, Fotte MA, Morstyn G: Hematopoietic growth factors in cancer chemotherapy, in Longo DL, Chabner BA (eds): Cancer Chemotherapy and Biological Response Modifiers. New York, NY, Elsevier Science, 1997, pp 363-389
6. Glaspy JA: Economic outcomes associated with the use of hematopoietic growth factors. Oncology 9:93-105, 1995 (suppl)
7. Lyman GH, Lyman CG, Sanderson RA, et al: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493, 1993
8. Armitage JO: Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92:4491-4508, 1998
9. Lyman GH, Balducci L: A cost analysis of hematopoietic colony stimulating factors. Oncology 9:85-91, 1995 (suppl)
10. Smith TJ: Role of granulocyte- and granulocyte-macrophage colony-stimulating factors in clinical practice: Balancing clinical and economic concerns. ASCO Educational Book, spring:275-280, 1999
11. Beveridge RA, Miller JA, Kales AN, et al: A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 16:366-373, 1998
12. Nattinger AB, Gottlieb MS, Veum J, et al: Geographic variation in the use of breast-conserving treatment for breast cancer. N Engl J Med 326:1102-1107, 1992
13. Lu-Yao GL, McLerran D, Wasson J, et al: An assessment of radical prostatectomy time trends, geographic variation and outcomes. JAMA 296:2633-2636, 1993
14. Davis DA, Thomson MA, Oxman AD, et al: Changing physician performance: A systematic review of the effect of continuing medical education strategies. JAMA 274:700-705, 1995
15. Hunt DL, Haynes RB, Hanna SE, et al: Effects of computer-based clinical decision support systems on physician performance in patient outcomes: A systematic review. JAMA 280:1339-1346, 1998
16. Mighion K, Gesme DH, Rifkin RM, et al: Growth of oncology physician practice management companies. Cancer Invest 17:362-370, 1999